ArticleCells2020
Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- The role of fibroblast growth factors in cell and cancer metabolism.FEBS letters · 2026Review
- Targeting neurotrophic dysregulation in diabetic retinopathy: a novel therapeutic avenue.Molecular biology reports · 2025Review
- Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.Molecular oncology · 2025Article
- Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B).Annals of neurology · 2024Article
- Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.BMC medical genomics · 2024Article
- Roles of fibroblast growth factors in the treatment of diabetes.World journal of diabetes · 2024Review
- MiR-1246b, a novel miRNA molecule of extracellular vesicles in bronchoalveolar lavage fluid, promotes nodule growth through FGF14 in patients with lung cancer.Cell death & disease · 2023Article
- Genome-wide mapping of gene-microbe interactions in the murine lung microbiota based on quantitative microbial profiling.Animal microbiome · 2023Article
- Construction of diagnostic and prognostic models based on gene signatures of nasopharyngeal carcinoma by machine learning methods.Translational cancer research · 2023Article
- Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment.Frontiers in oncology · 2022Review
- Long non-coding RNAPeerJ · 2022Article
- Review
- Collagen XI alpha 1 chain, a potential therapeutic target for cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Review
- Review
- Genomic relevance of FGF14 and associated genes on the prognosis of pancreatic cancer.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Investigation of the molecular dynamics in lung cancer is crucial for the development of new treatment strategies. Fibroblast growth factor (FGF) 14 belongs to the FGF family, which might play a crucial role in cancer progression. We analyzed lung adenocarcinoma (LUAC) patients samples and found that FGF14 was downregulated, correlating with reduced survival and oncogenic mutation status. FGF14 overexpression in lung cancer cell lines resulted in decreased proliferation, colony formation, and migration, as well as increased expression of epithelial markers and a decreased expression of mesenchymal markers, indicating a mesenchymal to epithelial transition in vitro. We verified these findings using small interfering RNA against FGF14 and further confirmed the suppressive effect of FGF14 in a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.